Maximize Market Research

Autoimmune Treatment Market to Nearly Double to $321.95B by 2034

Pune – September 24, 2026 -- The global autoimmune treatment market reached USD 176.6 billion in 2025 and is forecast to expand at a 6.9% CAGR through 2034, hitting USD 321.95 billion, according to a new analysis from Maximize Market Research.

North America dominates the market on strong pharmaceutical R&D infrastructure

North America held the largest share of the market in 2025, driven by high disease prevalence, advanced healthcare infrastructure, established specialist care and elevated healthcare spending. The United States anchors regional growth, backed by leading pharmaceutical and biotechnology firms, advanced diagnostic capacity, and rising adoption of biologics, immunosuppressants, monoclonal antibodies and targeted therapies. Canada and Mexico are contributing through improving healthcare access and disease awareness.

Nanomedicine Market to Nearly Triple to $581.2B by 2034

Pune, India – September 24, 2026 -- The global nanomedicine market reached USD 207.91 billion in 2025 and is projected to hit USD 581.2 billion by 2034, expanding at a 12.1% compound annual growth rate, according to a new report from Maximize Market Research.

North America commands the largest share on pharmaceutical R&D strength

North America held the largest share of the market in 2025, driven by advanced healthcare infrastructure, deep pharmaceutical and biotechnology research pipelines, and high healthcare expenditure. The United States anchors regional growth through its established research ecosystem and rising adoption of nanotechnology-based drug delivery, diagnostics and precision medicine platforms. Canada and Mexico are contributing through expanding healthcare capabilities and research initiatives.

MS Treatment Market to Hit $44.45B by 2034 on DMT Demand

Pune, India – September 24, 2026 -- The global multiple sclerosis treatment market reached USD 26.76 billion in 2025 and is forecast to climb to USD 44.45 billion by 2034, expanding at a 5.8% CAGR, according to a new report from Maximize Market Research.

Disease-modifying therapies and biologics drive current market expansion

Rising MS prevalence, improved diagnostic capabilities, and growing adoption of immunomodulators, immunosuppressants, interferons, oral disease-modifying therapies (DMTs), and monoclonal antibodies are fueling demand across relapsing-remitting (RRMS), primary progressive (PPMS), secondary progressive (SPMS), and clinically isolated syndrome (CIS) patient segments. High-efficacy biologics and oral treatment options are increasingly displacing older therapy classes as patients and physicians prioritize convenience and disease-progression control.

Bioinformatics Market to Hit $64.60B by 2034 on NGS, AI Demand

Pune – September 24, 2026 -- The global bioinformatics market is projected to expand from $20.34 billion in 2025 to $64.60 billion by 2034, a 13.7% compound annual growth rate, according to new analysis from Maximize Market Research.

Genomic data volumes and NGS adoption fuel core demand

Rising volumes of genomic and biological data, driven by expanding next-generation sequencing (NGS) adoption, are pushing pharmaceutical and biotechnology companies toward advanced bioinformatics platforms, sequencing data analysis tools, and biological databases. Declining sequencing costs are drawing smaller research institutions into the market, while growing precision medicine applications are increasing demand for pharmacogenomics, biomarker analysis, and genomic diagnostics.